Stem cells

It appears that the fad has already started fading. And the vain are letting their desire pass off - for the time being.

What is it that they are abstaining from? It is the prospect of many well-off individuals into submitting to stem cell therapy. The medical intervention uses live cells from mammals injected into a patient. It is widely done in a number of European cities.

The promised benefits from stem cell therapy, among others, is that it restores ''exuberance, alertness, and virility,'' hopefully, akin to those of a 20-year-old human being.

So, why is the enthusiasm and fascination of the procedure disappearing from among the country's moneyed sector - composed of the vain, the hypochondriacs, those who are eternally seeking the fountain of youth, and those who do not know what to do with their disposable moolah. (The therapy reportedly has a P500,000 price tag.)

For four consecutive days last week, media accounts about the contentious death of three congressmen after receiving stem cell therapy abroad dominated front-page stories and subsequent prime time TV news programs. (Manila Bulletin, June 25, 26 and 28, 2013)

Was their death blamed on stem cell therapy? News stories quoted relatives of the deceased as saying they succumbed to pneumonia. The 'Bulletin' story did not name the deceased.

But the Philippine Medical Association has always been suspicious of stem cell treatment. ''There are disadvantages,'' officials said. The statement reportedly claimed that the procedure done in Germany, for example, is ''xenogenic'' in substance. It involves the injection of animal-based stem cells to patients.

What the association apparently endorses is ''autologous'' stem cell treatment. The therapy is done with the use of the patient's own blood, bone marrow, and fat. Outside of this approach, the PMA apparently is skeptical as to their efficacy.

Another factor that is dousing cold water on prospective patients of stem cell therapy is fakery. We were informed via media reports of bootleg stem cell therapy here and overseas.

Certainly, it cannot be discounted that some patients who sought this kind of treatment ended up with dubious remedy being administered by non-medical persons or by pseudo-medical specialists.

Read more:
Stem cells

Type 2 Diabetes Patients Benefit From Bone Marrow Stem Cell Transplants

Editor's Choice Academic Journal Main Category: Diabetes Also Included In: Stem Cell Research;Transplants / Organ Donations Article Date: 01 Jul 2013 - 0:00 PDT

Current ratings for: Type 2 Diabetes Patients Benefit From Bone Marrow Stem Cell Transplants

The research, published in Cell Transplantation, was carried out in India and looked at the safety and efficacy of autologous transplanted bone marrow stem cells in patients with type 2 diabetes (TD2M).

Study corresponding author Anil Bhansali, PhD, professor and head of the Endocrinology Department at the Post Graduate Institute of Medical Education in Chandrigarh, India, said:

Although there is an increasing interest in using stem cell transplantation to treat people with this condition, there has been little research observing the benefit of bone marrow-derived stem cells.

"By experimenting with bone marrow-derived stem cells, the researchers sought to exploit the rich source of stem cells in bone marrow," the researchers said.

The experts wanted to examine the efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with T2DM and who also had good glycemic control.

Good glycemic control appeared as a critical factor in the transplantation group and in the non-transplanted control group.

Cell transplantation had a considerable influence on the patients in this report as those administered cells showed a significant decrease in insulin requirement.

A notably smaller decrease in the need for insulin was also observed in the control group.

Link:
Type 2 Diabetes Patients Benefit From Bone Marrow Stem Cell Transplants

UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials

Public release date: 1-Jul-2013 [ | E-mail | Share ]

Contact: Shaun Mason smason@mednet.ucla.edu 310-206-2805 University of California - Los Angeles

Researchers at UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have successfully established the foundation for using hematopoietic (blood-producing) stem cells from the bone marrow of patients with sickle cell disease to treat the disease. The study was led by Dr. Donald Kohn, professor of pediatrics and of microbiology, immunology and molecular genetics.

Sickle cell disease causes the body to produce red blood cells that are formed like the crescent-shaped blade of a sickle, which hinders blood flow in the blood vessels and deprives the body's organs of oxygen.

Kohn introduced an anti-sickling gene into the hematopoietic stem cells to capitalize on the self-renewing potential of stem cells and create a continual source of healthy red blood cells that do not sickle. The breakthrough gene therapy technique for sickle cell disease is scheduled to begin clinical trials by early 2014. The study was published online today ahead of press in the Journal of Clinical Investigation.

Kohn's gene therapy approach, which uses hematopoietic stem cells from a patient's own blood, is a revolutionary alternative to current sickle cell disease treatments as it creates a self-renewing normal blood cell by inserting a gene that has anti-sickling properties into hematopoietic stem cells. This approach also does not rely on the identification of a matched donor, thus avoiding the risk of rejection of donor cells. The anti-sickling hematopoietic stem cells are transplanted back into the patient's bone marrow and multiply the corrected cells that make red blood cells without sickling.

"The results demonstrate that our technique of lentiviral transduction is capable of efficient transfer and consistent expression of an effective anti-sickling beta-globin gene in human sickle cell disease bone marrow progenitor cells, which improved the physiologic parameters of the resulting red blood cells," Kohn said.

Kohn and colleagues found that in the laboratory the hematopoietic stem cells produced new non-sickled blood cells at a rate sufficient for significant clinical improvement for patients. The new blood cells survive longer than sickled cells, which could also improve treatment outcomes.

Sickle cell disease mostly affects people of Sub-Saharan African descent, and more than 90,000 patients in the U.S. have been diagnosed. It is caused by an inherited mutation in the beta-globin gene that makes red blood cells change from their normal shape, which is round and pliable, into a rigid, sickle-shaped cell. Normal red blood cells are able to pass easily through the tiniest blood vessels, called capillaries, carrying oxygen to organs such as the lungs, liver and kidneys. But due to their rigid structure, sickled blood cells get stuck in the capillaries.

Current treatments include transplanting patients with donor hematopoietic stem cells, which is a potential cure for sickle cell disease, but due to the serious risks of rejection, only a small number of patients have undergone this procedure and it is usually restricted to children with severe symptoms.

View original post here:
UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials

ResearchMoz.us: Stem Cells Market (Adult, Human Embryonic, Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell …

ALBANY, New York, July 1, 2013 /PRNewswire/ --

New Report Added in ResearchMoz Reports Database Stem Cells Market (Adult, Human Embryonic, Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell Production, Cell Acquisition, Expansion, Sub-Culture) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012-2018

ResearchMoz announces that it has published a new study Stem Cells Market (Adult, Human Embryonic, Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell Production, Cell Acquisition, Expansion, Sub-Culture)

Stem cells are undifferentiated cells which are capable of differentiating into any type of cell that make-up the human body and thus, are capable of producing non-regenerative cells such as neural and myocardial cells. This report estimates the market for global stem cells in terms of revenue (USD billion) for the period 2012 - 2018, keeping 2011 as the base year. The global stem cells market is mainly segmented into four major sub-types namely market by products, market by technology, market by applications and market by geography.

To Browse Full TOC, Tables & Figures visit:http://www.researchmoz.us/stem-cells-market-adult-human-embryonic-induced-pluripotent-rat-neural-umbilical-cord-cell-production-cell-acquisition-expansion-sub-culture-global-industry-analysis-size-share-growth-trends-and-forecast-2012-2018-report.html

The market by products is segmented into three sub-types, namely adult stem cells, human embryonic stem cells and other type of stem cells. Adult stem cells are further segmented into hematopoietic stem cells, mesenchymal stem cells, neuronal stem cells, dental stem cells and umbilical cord stem cells. The other types of stem cells include induced pluripotent stem cells, natural rosette cells and very small embryonic like stem cells.

The global stem cells market by technology is segmented into four sub-types, namely cell acquisition, cell production, cryopreservation and expansion and sub-culture. Cell acquisition is further segmented into three sub-types, namely bone marrow harvest, apheresis and umbilical cord blood. Cell production is further segmented into therapeutic cloning, in vitro fertilization, isolation and cell culture.

Latest Reports

Technical Textiles Market

Bitumen Market

Originally posted here:
ResearchMoz.us: Stem Cells Market (Adult, Human Embryonic, Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell ...

FCT Controversy: MY STEM CELL THERAPY STORY

By: Jesus G. Dureza Posted: July 1, 2013 8:28 am

Over the last few days, Fresh Stem Cell Therapy (FCT) got into the headlines due to some controversy involving alleged deaths and complaints mentioning prominent names blaming stem cell treatment for their alleged negative effects.Naturally, just like any controversy, the stories unduly put under cloud this innovative and pioneering science of regenerative medicine that is reputed to treat illnesses, bring well being and rejuvenation.

MY FRIENDS The current news reports caught public attention and went viral. Many friends who were following Beths FCT experience and who were planning to also undergo FCT were calling. They were bothered by the reports. I was myself personally disturbed because all of them who were mentioned as having experienced negative results, I knew in person. Congressman ERICO AUMENTADO of Bohol and Camiguin Congressman LOLOY ROMUALDO both were my close friends and whom I worked with when I was with the government. And the controversy all the more struck me because I and my wife Beth saw and experienced for ourselves the positive NOT NEGATIVE results of FCT seven months after treatment at VILLA MEDICA in Germany.

Let me trace back. I knew Congressman Erico well even when he was still Bohol Governor. His successful efforts in clearing his province of armed insurgency gained national attention. When I was Malacanang Presidential Peace Adviser, I used the Bohol experience as example of a success story. So, when initial reports surfaced about FCT having caused his death, I sat up and took special attention. Later, his son came out publicly DENYING the story saying his father died of pneumonia and NOT due to FCT. He said his fathers lungs were already in serious condition but after getting a first infusion of FCT, his condition suddenly and dramatically improved and he was hitting the election campaign trail like superman. In fact they were preparing to again return to Germany for another infusion encouraged by its initial favorable results when death intervened and overtook events.

The other prominent name mentioned with FCT was former Congressman Loloy. We were together as colleagues in Congress. The Romualdo family had dominated politically the Camiguin island province for a long time up to the present. The circumstances of his undergoing stem cell treatment , however, are not yet clear. My cursory check results showed that he did NOT get FCT from Villa Medica in Germany. This will have to be further validated though.

The other prominent name was former Customs official (and now with Dangerous Drugs Board) ANTONIO BEBOT VILLAR. We were together in the Arroyo administration. He said he and his wife had FCT in a 5-star hotel in Metro Manila, by German and Thai doctors but NOT in Germany. His condition allegedly worsened after the treatment. MY OWN STORY I will not venture to further deal on those incidents simply because they are now subject of further close look by the authorities. And I am not privy with the true facts surrounding their cases. But I will deal on some information that are of my own personal knowledge and the personal experience I and my wife BETH can competently attest to.

As I have written previously, I and my wife Beth traveled all the way to EDENKOBEN, GERMANY last November, 2012 some seven (7) months ago for FCT in the VILLA MEDICA (VM) clinic facilities as an alternative remedy to her deteriorating kidney condition. We were NOT assured that there would be positive results by VM representatives but we took the chance after I made extensive research and consultations with doctors and experts. We even traveled to Bangkok, Thailand to make further inquiries. We were encouraged by reports of well-being and regenerative effects on vital organs. And we took efforts to talk to those who themselves underwent the procedure. We gathered that VILLA MEDICA and its FCT, using fresh stem cell from the fetus of clinically controlled and raised sheep had been recognized, authorized, licensed and closely monitored by stringent standards imposed by GERMAN HEALTH AUTHORITIES of the German government. VILLA MEDICA, founded in 1963 had also a long track record of about 50 YEARS. Fresh cell therapy was pioneered by Dr PAUL NIEHANS in 1931. Another doctor in 1980, GUNTER BIOBEL scientifically dissected the technology and was awarded in 1999 the Nobel Prize in Physiology or Medicine.

After some soul-searching and weighing our options, we decided and took the trouble of traveling to Germany at some cost even when we were told that there were stem cell treatments also being done in the Philippines, at more considerable costs, although still in their infancy stage. We had no way of verifying the reliability of local Philippine FCT providers due to their fairly recent track record. When I checked with St. Lukes Hospital Regenerative division at Global City, the division chief told me they were into this procedure: harvesting human stem cells from the patients themselves, usually from the bone marrow, churn them for 2 weeks in the laboratory using German-made machines and injecting them back to the patient over a 12 month period. However she declined to cite or give an example of a success story simply because they had been into the procedure fairly recently. Also, we were informed that to achieve optimum results, fresh stem cells must be injected (in the buttocks) within two hours from its harvesting from the donor fetus. So getting the FCT infusion right there in the clinic in Germany was far better than having the injectables flown from Germany or elsewhere and get the infusion in Manila, travel time obviously reducing the stem cells efficacy or potency. More importantly, seven months ago, there were NO clear Philippine regulations yet governing FCT, due to its infancy, to give us some level of reasonable comfort and assurance. On the other hand, the procedure in Germany we were told adhered to strictest German standards imposed by the German government. These regulations even cover the growing and maintenance of donor sheep and the harvesting of stem cells from 18-week old fetus under clinical control and conditions. And specific success stories were many.

And more importantly, we were in a desperate mode due to the continuous decline of Beths kidney conditions. As preparatory steps, Beth went through a series of tests which were screened and studied by her doctors in Manila and even through German doctors in Villa Medica in Edenkoben who had to make the final decision whether she was qualified to get the treatment. Even her Nephrologist who happens to be also a family friend and a known kidney transplant surgeon at the National Kidney Institute recommended that we try FCT. That sealed our decision.

So, off we went to Germany last November, 2012. Of course at great expense. (Treatment costs EURO 15,000 or about 830,000 PHP ) But nonetheless. AFTER 7 MONTHS Today, seven months after the treatment, and in contrast to the sketchy stories surrounding the cases of my friends ERICO, LOLOY and BEBOT as reported in the media, our own testimonials of the FCT at VILLA MEDICA are a bit different from those horror stories. I also personally met and discussed with others who themselves went to the German facility for FCT and our testimonials coincided.

Read the original here:
FCT Controversy: MY STEM CELL THERAPY STORY

Parkinson’s Treatment With Pluripotent Stem Cell-Derived Neurons Shows Promise

Editor's Choice Academic Journal Main Category: Parkinson's Disease Also Included In: Stem Cell Research Article Date: 01 Jul 2013 - 0:00 PDT

Current ratings for: Parkinson's Treatment With Pluripotent Stem Cell-Derived Neurons Shows Promise

3 (2 votes)

The study - "Survival and Integration of Neurons Derived from Human Embryonic Stem Cells in MPTP Lesioned Primates" - has been published in the journal Cell Transplantation.

Dr. D. Eugene Redmond, Yale University School of Medicine, said "Parkinson's disease was one of the first neurological disorders to be studied for potential replacement of lost neurons. Since the 1970s there has been significant progress with learning the required gene expression, growth factors and culture conditions for differentiating cells into apparent dopamine neurons."

However, the authors explained that there have been disappointing results when transplanting dopamine neurons into rodents or monkeys - they did not become long-lasting midbrain specific neurons. They added that "there have only been pilot reports of functional improvement".

In this study, the scientists assessed the long-term survival of apparent dopamine neurons in monkeys modeled with Parkinson's-like symptoms. They also tested the functional benefit of the new neurons.

The authors found, as in previous studies, that gene expression of TH (tyrosine hydroxylase) was "transient" after transplantation. TH is a synthetic enzyme that limits dopamine production. They realized that they needed to determine when the optimal cell stage was, as well as the ideal culture environment for optimum graft survival, and also other factors that might influence the outcomes of cell transplantation.

The authors reported that there was better cell survival when a more robust immunosuppression regime was employed, compared to those used in previous primate studies.

The researchers wrote:

Link:
Parkinson's Treatment With Pluripotent Stem Cell-Derived Neurons Shows Promise

FDA urges hotels to guard vs stem cell therapy

By: Jet Villa, InterAksyon.com June 29, 2013 6:55 PM

A scientist working on stem cells in a laboratory. AGENCE FRANCE-PRESSE

InterAksyon.com The online news portal of TV5

MANILA, Philippines -- The Food and Drug Administration has asked hotels to guard against allowing stem cell therapy to be performed in their premises.

FDA acting director Dr. Kenneth Hartigan-Go said hotels may be held liable for guests found performing or undergoing stem cell therapy in their rooms.

Go pointed out that performing medical procedures like stem cell therapy in a non-health facility is illegal.

Under Republic Act 9711 or the Food and Drug Administration Act of 2009, violators face a fine of up to P500,000 plus closure of the establishment and jail terms.

In FDA Advisory 2013-012 issued May 15, the agency warned the pubic against "receiving unapproved stem cell preparations in non-health facilities."

"Patients who might receive stem cell preparations and therapy without prior FDA-Department of Health approval run the risks of contracting infectious diseases and severe complications which may lead to permanent disabilities, physical deformities, serious iatrogenic harm, autoimmune diseases and worst death, and without the benefit of health insurance coverage," the advisory said.

See the original post:
FDA urges hotels to guard vs stem cell therapy

Palace warns public on stem cell therapy

MALACAANG warned Friday the public from seeking stem cell therapy following the complaint by a government official of feeling weaker after undergoing this kind of treatment.

In a press briefing, deputy presidential spokesperson Abigail Valte said that the Department of Health (DOH) will issue an administrative order regarding the stem cell treatments in the country.

"The DOH received several reports regarding the stand-alone clinics which are offering (stem cell therapies) for skin rejuvenation to make you look younger. That's why the DOH has already acted on it. It just happened that there was an incident that was highlighted," she said.

Dangerous Drugs Board chairman Antonio Villar has admitted of undergoing recently stem cell therapy in an upscale hotel in Makati City in the hope to cure bone pains. He claimed of spending around P900,000 for the treatment. But he said he only felt weaker after the therapy.

Valte said that the public should be aware that stem cell therapies are only being undertaken in the DOH-accredited hospitals and not in any hotel or stand-alone clinics.

She also said that those being accredited are the hospitals and not the doctors.

"Come August 31, hospitals should file their accreditation requirements for them to continue to offer this treatment, if they offer that (treatment). So there's an accreditation process," she explained.

Valte said that she was also told that stem cell treatment is geared toward a certain purpose and not "cure all" ailments.

There are also certain sources that are only allowed by the DOH, in particular, the Food and Drug Administration, she said.

The official also urged the public to inform the authorities of any establishments or medical practitioners who have been violating the law.

More here:
Palace warns public on stem cell therapy

The prime of Charito Planas, 83, after stem cell therapy on the cheap

By Rima Jessamine Granali Philippine Daily Inquirer

Now she can literally walk a mile.

Lawyer Charito Planas, 83, used to have a hard time getting up. But she can now walk without pain, thanks to stem cell therapy that cost her only five figures.

While hospitals here and abroad charge millions for the treatment, a wellness center in Tagaytay offers the service 10 times cheaper, Planas said.

The cane I used to walk with is just an accessory now, for I walk freely, without pain, without limping, said Planas, a political and human rights activist who sought refuge in the United States during the Marcos martial law administration.

My heavily grey hair has now regained its ebony shade; my skinboth body and facial skinhas regained a youthful, shining glow; and my wrinkles are slowly fading away, she added.

Planas underwent six sessions of stem cell therapy from March to April at Green and Young Health and Wellness Center, owned by Dr. Antonia Carandang Park.

VIP patients

Former President Gloria Macapagal-Arroyo reportedly visited the Filipino physician a day after she was released from detention at Veterans Memorial Medical Center (VMMC) in Quezon City after posting a P1-million bail in July last year. She was taken back to VMMC in October.

Other well-known personalities, such as justices, physicians and a senator, also reportedly frequented the wellness center.

See original here:
The prime of Charito Planas, 83, after stem cell therapy on the cheap